CARgenix

**Clinical-stage start up, acquired by Sorrento Therapeutics's wholly-owned subsidiary, TNK Therapeutics in Aug 2015.** CARgenix is an innovative leader in the discovery, development, and delivery of chimeric antigen receptor (CAR) T-cell immunotherapies. Our clinically proven designer T-cell-based therapeutics platform harnesses the power of each patient’s immune system to treat solid-tumor cancers and infectious diseases. Specially engineered and personalized designer T cells (dTc’s) recognize disease-specific antigens to attack cancer cells, while minimizing off-target effects. Coupling innovative infusion and quick time-to-market strategies, CARgenix provides a unique platform in cancer drug development. Our firm embodies a distinctive scientific and business management foundation based on the rich experience of the firm’s founding leadership and an unparalleled go-to-market strategy that leverages advantageous institutional relationships.